Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting
- Wednesday, October 5, 2022, 7:14
- Environment
- Add a comment
SAN DIEGO, Oct. 5, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will…
About the Author
adminasapcorp has written 41546 stories on this site.